Close Menu

NEW YORK – Natera said after the close of the market on Thursday that on March 8, it terminated its license, development, and distribution agreement with Qiagen to develop and distribute next-gen sequencing-based genetic tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.